Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / MRK - Jounce Therapeutics: An Under The Radar And Undervalued Biotech

MRK - Jounce Therapeutics: An Under The Radar And Undervalued Biotech

Merck & Company Inc.
  • Jounce is a clinical stage biotech company that is attempting to transform the treatment of cancer by developing novel immunotherapies.
  • The science is promising, but still in its early stages.
  • A license deal with Gilead has provided credibility to Jounce's platform and helped to strengthen its cash position.
  • Currently at 1.13x book value, shares of Jounce look cheap and present an investment opportunity with a favorable risk-reward profile.

For further details see:

Jounce Therapeutics: An Under The Radar And Undervalued Biotech
Stock Information
Company Name: Merck & Company Inc.
Stock Symbol: MRK
Market: NYSE
Website: merck.com
Menu
MRK MRK Quote MRK Short MRK News MRK Articles MRK Message Board
Get MRK Alerts

News, Short Squeeze, Breakout and More Instantly...